Jacobio Pharmaceuticals (HKG:1167) completed dosing of the first patient for the phase 1/2a of its clinical trial or its JAB-23E73 anti-cancer drug in China, according to a Monday filing with the Hong Kong Exxchange.
The drug is an inhibitor of the Ki-ras2 Kirsten rat sarcoma viral oncogene homolog or KRAS, which is seen in various tumor mutations, the filing said.
Shares rose 1% during Monday's afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.